- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
The Cost of Cancer Care
As Ezra pointed out recently, the cost of your health care depends a lot on where you live. An MRI that costs $1,080 here in the United States would come in at $280 in France. Even within the United States, there’s big variation in how much we pay for the exact same treatment.
Not all health care cost variation, however, has to do with geography: It turns out that what kind of facility you seek treatment at matters a lot, too. An episode of cancer treatment costs 24 percent more at a hospital than if the same course of treatment were carried out at a doctor’s office, according to a new analysis from Avalere Health.
The Avalere study aimed to compare the net costs, everything paid by both the patient and the insurance company, of patients’ course of treatment. It compares cancer care that’s managed by a doctor’s office (about 75 percent of current treatments) versus those overseen by a hospital. They controlled for patients’ age, gender, length of cancer treatment and prior cancer history.
Read the full story: http://hcp.lv/HgqNSs
Source: The Washington Post
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
Texas Oncology to Roll Out Canopy for ePROs After Head-to-Head Pilot
March 18th 2025Debra Patt, MD, PhD, MBA, executive vice president of Public Policy and Strategy for Texas Oncology, said the practice received positive feedback from nurses and patients during a pilot that concluded in February.
Read More
For Neuromuscular Disease Community, an Era of Opportunities and Threats
March 17th 2025Robert Califf, MD, former commissioner of the FDA, delivered a keynote address at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference that highlighted the enormous opportunities for progress in neuromuscular disease care amid a changing policy environment.
Read More
